Total Valuation
Lakewood-Amedex Biotherapeutics Inc. has a market cap or net worth of $5.17M. The enterprise value is ―.
Market Cap$5.17M
Enterprise Value―
Share Statistics
Lakewood-Amedex Biotherapeutics Inc. has 2,369,688 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,369,688
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Lakewood-Amedex Biotherapeutics Inc.’s return on equity (ROE) is 1.96 and return on invested capital (ROIC) is 1240.11%.
Return on Equity (ROE)1.96
Return on Assets (ROA)-7.99
Return on Invested Capital (ROIC)1240.11%
Return on Capital Employed (ROCE)1.96
Revenue Per Employee0.00
Profits Per Employee-769.53K
Employee Count5
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lakewood-Amedex Biotherapeutics Inc. is ―. Lakewood-Amedex Biotherapeutics Inc.’s PEG ratio is 0.52.
PE Ratio―
PS Ratio0.00
PB Ratio-61.36
Price to Fair Value-61.36
Price to FCF-61.99
Price to Operating Cash Flow-0.94
PEG Ratio0.52
Income Statement
In the last 12 months, Lakewood-Amedex Biotherapeutics Inc. had revenue of 0.00 and earned -3.85M in profits. Earnings per share was -2.76.
Revenue0.00
Gross Profit0.00
Operating Income-3.77M
Pretax Income-3.85M
Net Income-3.85M
EBITDA-3.63M
Earnings Per Share (EPS)-2.76
Cash Flow
In the last 12 months, operating cash flow was -3.49M and capital expenditures 0.00, giving a free cash flow of -3.49M billion.
Operating Cash Flow-3.49M
Free Cash Flow-3.49M
Free Cash Flow per Share-1.47
Dividends & Yields
Lakewood-Amedex Biotherapeutics Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.31
52-Week Price Change-97.32%
50-Day Moving Average2.56
200-Day Moving Average―
Relative Strength Index (RSI)40.02
Average Volume (3m)728.15K
Important Dates
Lakewood-Amedex Biotherapeutics Inc. upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Lakewood-Amedex Biotherapeutics Inc. as a current ratio of 0.13, with Debt / Equity ratio of 2.35%
Current Ratio0.13
Quick Ratio0.13
Debt to Market Cap0.01
Net Debt to EBITDA-0.39
Interest Coverage Ratio-37.39
Taxes
In the past 12 months, Lakewood-Amedex Biotherapeutics Inc. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Lakewood-Amedex Biotherapeutics Inc. EV to EBITDA ratio is -33.63, with an EV/FCF ratio of -62.72.
EV to Sales0.00
EV to EBITDA-33.63
EV to Free Cash Flow-62.72
EV to Operating Cash Flow-62.72
Balance Sheet
Lakewood-Amedex Biotherapeutics Inc. has $4.58M in cash and marketable securities with $101.62K in debt, giving a net cash position of $4.48M billion.
Cash & Marketable Securities$4.58M
Total Debt$101.62K
Net Cash$4.48M
Net Cash Per Share$1.89
Tangible Book Value Per Share-$1.41
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Lakewood-Amedex Biotherapeutics Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-140.44%